Integrated Biopharma Stock Annual Yield
Integrated Biopharma fundamentals help investors to digest information that contributes to Integrated Biopharma's financial success or failures. It also enables traders to predict the movement of Integrated OTC Stock. The fundamental analysis module provides a way to measure Integrated Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Biopharma otc stock.
Integrated |
Integrated Biopharma OTC Stock Annual Yield Analysis
Integrated Biopharma's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
CompetitionIn accordance with the recently published financial statements, Integrated Biopharma has an Annual Yield of 0.0%. This indicator is about the same for the Personal Products average (which is currently at 0.0) sector and about the same as Consumer Staples (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Integrated Annual Yield Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Biopharma's direct or indirect competition against its Annual Yield to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Integrated Biopharma could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics of similar companies.Integrated Biopharma is currently under evaluation in annual yield category among its peers.
Integrated Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 12.05 M | ||||
| Shares Outstanding | 29.95 M | ||||
| Shares Owned By Insiders | 68.58 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Price To Earning | 2.52 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 0.21 X | ||||
| Revenue | 56.25 M | ||||
| Gross Profit | 6.55 M | ||||
| EBITDA | 3.54 M | ||||
| Net Income | 3.84 M | ||||
| Cash And Equivalents | 343 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 53 K | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | 4.09 M | ||||
| Earnings Per Share | 0.11 X | ||||
| Number Of Employees | 147 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 11.2 M | ||||
| Total Asset | 25.25 M | ||||
| Retained Earnings | (59.89 M) | ||||
| Working Capital | 913 K | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 11.79 M | ||||
| Net Asset | 25.25 M |
Pair Trading with Integrated Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Helmerich could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helmerich when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helmerich - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helmerich and Payne to buy it.
The correlation of Helmerich is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helmerich moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helmerich and Payne moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helmerich can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |